相关实验视频
Updated: Jan 18, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
在1型和2型糖尿病中每周服用一次胰岛素的新兴观点:一个小小的回顾
1Université Bourgogne Europe, CHU Dijon Bourgogne, Department of Clinical Biochemistry, INSERM, CTM UMR 1231, PADYS team, Dijon, France.
Frontiers in endocrinology
|September 12, 2025
概括
每周一次的基础胰岛素,如icodec和efsitora,对糖尿病管理具有前景,在2型糖尿病中提供与日常选择相比的HbA1c降低. 然而,在1型糖尿病试验中观察到更高的低血糖率.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 每周一次的基础胰岛素类似物,包括胰岛素icodec和efsitora alfa,正在成为糖尿病的创新治疗方法.
- 这些新型疗法旨在减少注射的频率,潜在地提高患者的坚持和简化糖尿病管理.
研究的目的:
- 审查最近的临床试验研究结果,以评估每周一次基础胰岛素治疗的有效性和安全性.
- 为了比较这些新疗法与既定的每日一次基础胰岛素方案,在1型和2型糖尿病中.
主要方法:
- 随机临床试验的系统综述,评估每周一次的胰岛素icodec和efsitora alfa.
- 对不同患者群体的疗效 (降低HbA1c) 和安全性 (低血糖率) 数据的分析.
主要成果:
- 在2型糖尿病中,每周服用一次的胰岛素与每天服用一次的基本胰岛素相比,表现不逊色,有时甚至优越,安全性概况令人放心.
- 在1型糖尿病中,每周服用一次胰岛素与每天服用一次降血糖相比,HbA1c的降低同样可见,但低血糖率更高.
- 与单个药物相比,icodec和semaglutide (IcoSema) 的固定比例组合显示出优异的HbA1c降低.
结论:
- 每周一次的基础胰岛素为治疗2型糖尿病提供了一种可行的替代方案,可与每日注射相比,具有可比或改进的血糖控制.
- 需要进一步的研究来确定这些新型胰岛素配方的长期心血管结果和安全性,特别是在1型糖尿病中.
- 每周使用一次胰岛素的开发代表了在减轻糖尿病患者治疗负担方面取得的重大进展.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
695
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
695
Insulin Formulations: Types and Delivery
663
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
663
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Diabetes: Management and Pharmacotherapy
870
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
870
Diabetes Mellitus: Type 2 and Gestational
4.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.4K
Insulin: The Receptor and Signaling Pathways
2.8K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.8K

